Moderna

Moderna has begun a Phase 1 clinical trial of an Ebola vaccine targeting the Zaire strain responsible for the outbreak in the Democratic Republic of the Congo. The trial marks the first human testing of the candidate, which uses the same mRNA technology behind Moderna's COVID-19 vaccine. Coverage is highlighting the company's growing pipeline and the urgent need for new Ebola countermeasures in central Africa.

The updated 2026-2027 COVID-19 vaccine has rolled out in the United States, with people booking Moderna booster appointments at pharmacies such as Walgreens. The news comes as a COVID update reports a 13th wave underway, with outbreaks in 40 states and territories and an estimated 3.8 million new infections, prompting renewed calls to get the latest shot.